Alvaro Ingles Garces

Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors

Malaka Ameratunga, Maxime Chénard-Poirier, Irene Moreno Candilejo et al. · European Journal of Cancer · 2017 · 76 citations

Medicine, Hematology, Oncology +16

First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors

Robert McLeod, Rajiv Kumar, Dionysis Papadatos-Pastos et al. · Clinical Cancer Research · 2020 · 68 citations · Full text

Medicine, Oncology, Pharmacology +17

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Bristi Basu, Matthew Krebs, Raghav Sundar et al. · Annals of Oncology · 2018 · 34 citations · Full text

Medicine, Oncology, Pharmacology +17

Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions

Milena Guimaraes, Dirceu Bartolomeu Greco, Alvaro Ingles Garces et al. · International Journal of Clinical Practice · 2010 · 31 citations

Medicine, Cardiology, Infectious Diseases +17

A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I

Andréia Cristina de Melo, Rachele Grazziotin-Reisner, Felipe Erlich et al. · Cancer Chemotherapy and Pharmacology · 2016 · 31 citations

Medicine, Oncology, Pharmacology +14